These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

720 related items for PubMed ID: 15712082

  • 1. Influence of liver fibrosis on highly active antiretroviral therapy-associated hepatotoxicity in patients with HIV and hepatitis C virus coinfection.
    Aranzabal L, Casado JL, Moya J, Quereda C, Diz S, Moreno A, Moreno L, Antela A, Perez-Elias MJ, Dronda F, Marín A, Hernandez-Ranz F, Moreno A, Moreno S.
    Clin Infect Dis; 2005 Feb 15; 40(4):588-93. PubMed ID: 15712082
    [Abstract] [Full Text] [Related]

  • 2. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections.
    Sulkowski MS, Thomas DL, Mehta SH, Chaisson RE, Moore RD.
    Hepatology; 2002 Jan 15; 35(1):182-9. PubMed ID: 11786975
    [Abstract] [Full Text] [Related]

  • 3. Prospective, open-label comparative study of liver toxicity in an unselected population of HIV-infected patients treated for the first time with efavirenz or nevirapine.
    Manfredi R, Calza L, Chiodo F.
    HIV Clin Trials; 2005 Jan 15; 6(6):302-11. PubMed ID: 16452064
    [Abstract] [Full Text] [Related]

  • 4. No increased risk of hepatotoxicity in long-term use of nonnucleoside reverse transcriptase inhibitors in HIV-infected patients.
    Van Welzen B, Mudrikova T, Arends J, Hoepelman A.
    HIV Med; 2012 Aug 15; 13(7):448-52. PubMed ID: 22413955
    [Abstract] [Full Text] [Related]

  • 5. Risk of severe hepatotoxicity associated with antiretroviral therapy in the HIV-NAT Cohort, Thailand, 1996-2001.
    Law WP, Dore GJ, Duncombe CJ, Mahanontharit A, Boyd MA, Ruxrungtham K, Lange JM, Phanuphak P, Cooper DA.
    AIDS; 2003 Oct 17; 17(15):2191-9. PubMed ID: 14523276
    [Abstract] [Full Text] [Related]

  • 6. Highly active antiretroviral therapy-related hepatotoxicity in human immunodeficiency virus and hepatitis C virus co-infected patients with advanced liver fibrosis in Taiwan.
    Chou CC, Tsai HC, Wu KS, Sy CL, Chen JK, Chen YS, Lee SS.
    J Microbiol Immunol Infect; 2016 Aug 17; 49(4):546-53. PubMed ID: 25440980
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Liver injury in HIV-1-infected patients receiving non-nucleosides reverse transcriptase inhibitors-based antiretroviral therapy.
    Li ZC, Li HJ, Dai LL, Gao YQ, Cai WP, Li HY, Huang XJ, Zhang T, Wu H.
    Chin Med J (Engl); 2010 Dec 17; 123(24):3587-90. PubMed ID: 22166636
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Progression of liver fibrosis in HIV/hepatitis C virus-coinfected individuals on antiretroviral therapy with early stages of liver fibrosis at baseline.
    Sanmartín R, Tor J, Sanvisens A, López JJ, Jou A, Muga R, Ojanguren I, Barluenga E, Videla S, Planas R, Clotet B, Tural C.
    HIV Med; 2014 Apr 17; 15(4):203-12. PubMed ID: 24245909
    [Abstract] [Full Text] [Related]

  • 14. Effect of liver fibrosis on long-term mortality in HIV/hepatitis C virus-coinfected individuals who are evaluated to receive interferon therapies in the highly active antiretroviral therapy era.
    Sanmartin R, de Felipe E, Tor J, Sanvicens A, Barluenga E, Martinez E, Muga R, Jou A, Ojanguren I, López JJ, Clotet B, Tural C.
    AIDS Res Hum Retroviruses; 2012 Oct 17; 28(10):1235-43. PubMed ID: 22443303
    [Abstract] [Full Text] [Related]

  • 15. Hepatotoxicity of antiretroviral drugs is reduced after successful treatment of chronic hepatitis C in HIV-infected patients.
    Labarga P, Soriano V, Vispo ME, Pinilla J, Martin-Carbonero L, Castellares C, Casado R, Maida I, Garcia-Gasco P, Barreiro P.
    J Infect Dis; 2007 Sep 01; 196(5):670-6. PubMed ID: 17674307
    [Abstract] [Full Text] [Related]

  • 16. Analysis of severe hepatic events associated with nevirapine-containing regimens: CD4+ T-cell count and gender in hepatitis C seropositive and seronegative patients.
    Torti C, Costarelli S, De Silvestri A, Quiros-Roldan E, Lapadula G, Cologni G, Paraninfo G, Castelnuovo F, Puoti M, Carosi G, BHCC Study Group.
    Drug Saf; 2007 Sep 01; 30(12):1161-9. PubMed ID: 18035868
    [Abstract] [Full Text] [Related]

  • 17. Liver stiffness and aspartate aminotransferase levels predict the risk for liver fibrosis progression in hepatitis C virus/HIV-coinfected patients.
    Gonzalez FA, Van den Eynde E, Perez-Hoyos S, Navarro J, Curran A, Burgos J, Falcó V, Ocaña I, Ribera E, Crespo M.
    HIV Med; 2015 Apr 01; 16(4):211-8. PubMed ID: 25234826
    [Abstract] [Full Text] [Related]

  • 18. Lack of hepatotoxicity associated with nonnucleoside reverse transcriptase inhibitors.
    Palmon R, Koo BC, Shoultz DA, Dieterich DT.
    J Acquir Immune Defic Syndr; 2002 Apr 01; 29(4):340-5. PubMed ID: 11917237
    [Abstract] [Full Text] [Related]

  • 19. Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy.
    Martínez E, Blanco JL, Arnaiz JA, Pérez-Cuevas JB, Mocroft A, Cruceta A, Marcos MA, Milinkovic A, García-Viejo MA, Mallolas J, Carné X, Phillips A, Gatell JM.
    AIDS; 2001 Jul 06; 15(10):1261-8. PubMed ID: 11426070
    [Abstract] [Full Text] [Related]

  • 20. Effect of antiretroviral drugs on liver fibrosis in HIV-infected patients with chronic hepatitis C: harmful impact of nevirapine.
    Macías J, Castellano V, Merchante N, Palacios RB, Mira JA, Sáez C, García-García JA, Lozano F, Gómez-Mateos JM, Pineda JA.
    AIDS; 2004 Mar 26; 18(5):767-74. PubMed ID: 15075511
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 36.